← Leaderboards
Catherine A Spino
University Of Michigan At Ann Arbor
$34,285,809
Attributed
$41,720,169
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $8.5M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$41,720,169 · 9
By mechanism
U24$26,940,006 · 4
U01$7,775,389 · 1
R33$5,723,087 · 1
P50$827,891 · 2
R61$453,796 · 1
Top collaborators
- Kevin R Flaherty6 shared
- Harold A Chapman5 shared
- Fernando J Martinez5 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Salah-Uddin Ahmed$5,934,074
- Kevin R Flaherty$9,330,908
- Johann Eli Gudjonsson$13,584,665
- Xudong Fan$6,206,272
- Kyle Jerome Gunnerson$870,130
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignEnsureCollaborationsResearch PersonnelDatabasesUniversitiesMichiganProtocols DocumentationOnline SystemsReportingMonitorAdherenceWeb SiteClinical ResearchStatistical MethodsData ManagementSuccessData CollectionClinical Research SiteCommunicationData Coordinating CenterStatistical Data InterpretationAdverse EventDiagnostic
Grant awards (33)
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$3,790,120
U24 · FY2025 · DK · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,763,207
R33 · FY2025 · HL
2/2 A Phase 2 Study of Elafin (Tiprelestat) for the Treatment of Pulmonary Arterial Hypertension (PAH)$936,858
U24 · FY2025 · HL · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$408,088
U24 · FY2025 · HL · contact PI
Core D: Biostatistics and Data Management Core$167,326
P50 · FY2025 · NS · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$3,861,668
U24 · FY2024 · DK · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$1,758,766
R33 · FY2024 · HL
2/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$944,023
U24 · FY2024 · HL · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$627,206
U24 · FY2024 · HL · contact PI
Core D: Biostatistics and Data Management Core$158,587
P50 · FY2024 · NS · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$48,139
R33 · FY2024 · HL
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$3,767,901
U24 · FY2023 · DK · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$2,152,975
R33 · FY2023 · HL
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,346,213
U24 · FY2023 · HL · contact PI
2/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$928,890
U24 · FY2023 · HL · contact PI
Core D: Biostatistics and Data Management Core$167,326
P50 · FY2023 · NS · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$138,934
U24 · FY2023 · DK · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,793,103
U24 · FY2022 · HL · contact PI
2/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$932,716
U24 · FY2022 · HL · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$556,630
U24 · FY2022 · DK · contact PI
Phase 1 study of oral epigallocatechin-3-gallate (EGCG) in IPF patients$453,796
R61 · FY2022 · HL
Core D: Biostatistics and Data Management Core$167,326
P50 · FY2022 · NS · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$1,875,962
U24 · FY2021 · HL · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$1,439,556
U24 · FY2021 · DK · contact PI
2/2 Doxycycline for Emphysema in People Living with HIV: The DEPTH Trial$863,939
U24 · FY2021 · HL · contact PI
Core D: Biostatistics and Data Management Core$167,326
P50 · FY2021 · NS · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$769,940
U24 · FY2020 · DK · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$626,505
U24 · FY2020 · DK · contact PI
University of Michigan Data Coordinating Center for the Diabetic Foot Consortium$749,449
U24 · FY2019 · DK · contact PI
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases study$582,305
U24 · FY2019 · HL · contact PI
Pelvic floor Disorders Network-Data Coordinating Center$2,652,472
U01 · FY2009 · HD · contact PI
Pelvic floor Disorders Network-Data Coordinating Center$2,668,707
U01 · FY2008 · HD · contact PI
Pelvic floor Disorders Network-Data Coordinating Center$2,454,210
U01 · FY2007 · HD · contact PI